Eledon Pharmaceuticals, Inc. (ELDN) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
19900 MacArthur Boulevard
Irvine, CA 92612
United States of America (the)
Phone
949 238 8090
Website
Sector
Healthcare
Industry
Biotechnology
Employees
31
First IPO Date
September 17, 2014
| Name | Title | Pay | Year Born |
| David-Alexandre C. Gros | Chief Executive Officer & Non Independent Director | 984,408 | 1972 |
| Bryan E. Smith | General Counsel, Corporate Secretary & Chief Compliance Officer | 377,136 | 1980 |
| Paul Sean Little | Chief Financial Officer | 717,378 | 1965 |
| Steven N. Perrin | President, Chief Scientific Officer & Non Independent Director | 792,156 | 1966 |
| Eliezer Katz | Chief Medical Officer | 0 | N/A |
| David Hovland | Chief Regulatory Officer | 0 | N/A |
| John Herberger | Vice President of Technical Operations | 0 | N/A |
| Marina Escudero | Vice President & Head of Clinical Operations | 0 | N/A |
Eledon Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating innovative treatments for individuals battling autoimmune disorders, amyotrophic lateral sclerosis (ALS), and those undergoing organ or cell transplantation. Their flagship therapeutic candidate, AT-1501, is a humanized monoclonal antibody engineered to specifically target CD40 Ligand, a crucial protein found on the surface of immune system T cells. This compound is currently undergoing Phase 2a clinical studies for ALS treatment and Phase 2 trials for islet cell transplantation, aiming to address type 1 diabetes. Previously known as Novus Therapeutics, Inc., the company adopted its current name, Eledon Pharmaceuticals, Inc., in January 2021. Its corporate headquarters are located in Irvine, California.